iLite® IL-23 Assay Ready Cells are a genetically engineered reporter gene cell line, optimized to respond to IL-23 with specific, proportional expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promotor.
The iLite® IL-23 Assay Ready Cells can be used for the quantification of IL-23 or p40 inhibitor activity, or the neutralizing antibody response against such inhibitors in human serum.
Application notes for the following assays are available:
Interleukin 23 (IL-23) is a heterodimeric pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions. IL-23 has been implicated as an inflammation mediator in several autoimmune diseases, and has also been found to promote tumour growth. Therapeutic agents targeting both IL-12 and IL-23 cytokines are currently used to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders.
>250 µL of Assay Ready Cells suspended in RPMI 1640 medium with 20% heat inactivated fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO).